Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Authors: Ana Strezova, Javier Díez‐Domingo, Kamal Al Shawafi, Juan Carlos Tinoco, Meng Shi, Paola Pirrotta, Agnes Mwakingwe-Omari, Zoster-049 Study Group, Michael A. Adams, Anitta Ahonen, Charles P. Andrews, Eugene Athan, Jose-Fernando Barba-Gómez, Piero Barbanti, Elisabeth Barberan, Alain Baty, Niklas Bengtsson, Juergen Berger-Roscher, Katarina Berndtsson Blom, Jean Beytout, Loïc Boucher, Céline Boutry, Alain Boye, François Brault, Laurie Breger, Carles Brotons Cuixart, Covadonga Caso, Christine Cerna, Huey‐Shinn Cheng, Hee Jin Cheong, Eun Ju Choo, Clóvis Cunha, Anthony L. Cunningham, Dan Curiac, Benoit Daguzan, Antje Dahmen, Susan Datta, Maria Giuseppina Desole, Emmanuel Di Paolo, Marc Dionne, Petr Dítě, Jan Dutz, John Earl, Tamara Eckermann, William Ellison, Jurij Eremenko, Meral Esen, Takashi Eto, Xavier Farrés Fabré, Cecil Farrington, Murdo Ferguson, Pierre André Ferrand, Matthew Finneran, David Francyk, Marshall Freedman, George Freeman, Antônio Tarcísio Freire, Péter Gál, Jean-Sebastien Gauthier, Beatrice Gerlach, Wayne Ghesquière, Iris Gorfinkel, Christine Grigat, Josef Großkopf, Mónika Inés Hamann, Pascal Hanrion, Paul Hartley, Andrew Hastie, Ken Heaton, Agnes Himpel-Boenninghoff, Thomas Horacek, David S.C. Hui, Yieng Huong, Shinn‐Jang Hwang, Giancarlo Icardi, Gabriele Illies, Junya Irimajiri, Wilson Jacob, Alen Jambrecina, Thiago Junqueira Avelino‐Silva, George Kalema, Hyo Youl Kim, Christiane Klein, Uwe Kleinecke, Hans-Joachim Koenig, Satu Kokko, Pavel Kosina, Susanna Koski, Pekka Koskinen, Maximilian Kropp, Rie Kuroki, Outi Laajalahti, Pierre Lachance, Jacob Lee, Jin Soo Lee, Peter Levins, Robert Lipetz, Bo Liu, Chiu-Shong Liu, Martin Lundvall, Luci Magimaiseelan, Mary Beth Manning, Jukka Markkula, Frederick N. Martin, Pyrene Martínez Piera, Damien McNally, Shelly McNeil, Guglielmo Migliorino, Beate Moeckesch, Stephan Morscher, Michael Mueller, Abul Kashem Munir, Cláudia Murta de Oliveira, Kenjiro Nakamura, Silvia Narejos Pérez, Yuji Naritomi, Patrice Nault, José Luiz Costa Neto, Concepción Núñez López, Hiroaki Ogata, Åke Olsson, Pauliina Paavola, Dae Won Park, Janice Patrick, Karlis Pauksens, Mercè Pérez Vera, L Peltonen, Georg Plassmann, Airi Põder, Terry L. Poling, Carol Pretswell, Samir Purnell-Mullick, George Raad, T. Michael Redmond, Philippe Remaud, Ernie Riffer, P. C. Robert, Alex Rodríguez Badia, María Luisa Rodríguez de la Pinta, Lars Rombo, Robert Rosen, Shari E. Rozen, Dominique Saillard, Bruno Salaun, Johan Berglund, Joachim Sauter, Axel Schaefer, Isabelle Schenkenberger, Schmidt Juergen, Bernhard Schmitt, Schubert Christian, Anne Schuind, Tino Schwarz, Ilkka Seppä, Edmund Kwok Yiu Sha, Gerald Shockey, Sylvia Shoffner, Elina Sirnela-Rif, Tommaso Staniscia, Hirohiko Sueki, Suzuki Shin, Denis Taminau, Guy Tellier, Manuel Terns Riera, Azhar Toma, Nicole Toursarkissian, M. Turner, Benita Ukkonen, Anna Vilella Morató, Juergen Wachter, Brian Webster, Karl Wilhelm, Jonathan Wilson, Wilfred Yeo, Chong‐Jen Yu, Toufik Zahaf, Irina Zahharova, Cristiano A. F. Zerbini - Open Forum Infectious Diseases 2022 cited by 101

Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.